TARDBP and amyotrophic lateral sclerosis: The pharmacological inhibition of NF-κB activity significantly reduced the vulnerability of neurons overexpressing TDP-43 to toxicity induced by microglia and glutamate, identifying NF-κB as a potential therapeutic target for ALS.